Codetol

Quick links to important sections

Codetol

Method of action: Antitussive Opioid

Treatment option: Cough

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Codetol

Property Description
Active ingredient Codeine (often as Codeine phosphate)
Form Tablet, capsule, or oral solution
Pharmacological class Opioid Analgesic and Antitussive
General purpose Pain management and cough suppression
Origin Semi-synthetic opioid

What Type of Medicine is Codetol?

Codetol is a prescription-only medicinal product containing Codeine, an active ingredient classified as a semi-synthetic opioid and a pro-drug. It is categorized within the opioid analgesic and antitussive pharmacological classes. This classification reflects its two primary functions: reducing pain perception and suppressing the cough reflex through its action on the central nervous system.

Codeine is derived from the natural alkaloid Morphine but requires chemical modification, defining its semi-synthetic nature. As a pro-drug, it is biologically converted into active compounds within the body to exert its therapeutic effects. This action is based on its structural relationship to the natural opium alkaloids.

Composition and Available Forms of Codetol

The formulation utilizes Codeine as the active ingredient, most frequently prepared as the stable salt, Codeine phosphate. This drug is intended for the oral route of administration and is available as a pharmaceutical preparation in multiple common dosage forms, a feature that provides distinct flexibility for patient groups.

This medication is produced as an oral solid, such as a tablet or capsule, or as an aqueous oral solution (syrup), contained within a liquid vehicle base. The availability in liquid form often targets adolescents or individuals who face difficulties swallowing tablets. Furthermore, Codeine is available as a single-ingredient product and widely as a fixed-dose combination product, paired with other non-opioid active substances.

What is the General Purpose of Codetol?

The general purpose of Codetol is to achieve therapeutic comfort by influencing key functions of the central nervous system. As an opioid analgesic, the drug is intended for pain management, such as alleviating moderate acute physical discomfort. Its simultaneous designation as an antitussive means the drug is also utilized for the relief and suppression of unproductive, persistent coughing. The mechanism involves decreasing brain activity related to these sensations. This combined action defines the overarching utility of Codetol.

Regulatory References

  1. Codeine Structure NIH
  2. NIH Codeine Drug Information

What side effects are possible with Codetol?

Possible side effects and safety information for Codetol

The safety profile of Codetol (Codeine) is primarily structured by classifying potential reactions according to their frequency and the body system affected, as documented in official government regulatory documents.

Adverse Reaction Scope

Classification Examples of Officially Documented Effects
Very Common Constipation (Gastrointestinal disorders).
Common Nausea, Vomiting, Sedation, Dizziness, Headache (Nervous system and Gastrointestinal disorders).
Uncommon Pruritus (Itching), Rash, Diaphoresis/Sweating (Skin disorders); Confusion.

Serious Adverse Reactions

Official labels highlight the risk of Life-Threatening Respiratory Depression, which can occur at any time, with the greatest risk upon treatment initiation or following a dose increase. Other serious adverse reactions documented include Serotonin Syndrome (when used with certain other medications) and severe hypersensitivity reactions such as Anaphylaxis.

Population-Specific Safety Constraints

Codetol is contraindicated in several specific populations due to heightened risk, including all children younger than 12 years of age. It is also contraindicated in individuals of any age who are known to be CYP2D6 ultra-rapid metabolizers, a genetic variation that leads to dangerously high levels of the active drug metabolite. Furthermore, use is strictly contraindicated in children under 18 years of age following tonsillectomy or adenoidectomy and in women who are breastfeeding.

Duration-Related Safety Patterns

Regulatory documents note that Physical Dependence and Tolerance are conditions officially associated with prolonged or chronic use. The possibility of a Withdrawal Syndrome upon abrupt cessation following long-term exposure is also documented. The official safety profile is also marked by strict contraindications for patients with significant respiratory depression or known gastrointestinal obstructions, such as paralytic ileus.

Overdose and Emergency Response

The regulatory documentation for Codetol (Codeine) defines overdose through severe central nervous system (CNS) and respiratory depression. Immediate medical attention must be sought if overdose is suspected; do not delay contacting emergency services or a poison control center.

Documented Overdose Manifestations

Physiological System Officially Documented Manifestation
CNS Somnolence, confusion, lethargy, progression to coma.
Respiratory Respiratory depression, shallow breathing, cyanosis.
Ocular Pinpoint pupils (miosis).

Severe Outcomes and Emergency Management

Life-threatening outcomes officially associated with severe overdose include respiratory arrest, which is the primary danger, along with potential for circulatory collapse and cardiac arrest. The specific opioid antagonist Naloxone is listed in regulatory documentation for acute management. Treatment protocols require immediate supportive and symptomatic care, including establishing a patent airway and ensuring adequate ventilation. Continuous monitoring of vital signs in a hospital observation setting is required. A specific risk for severe respiratory effects is officially documented for pediatric patients and the elderly.

Therapeutic Uses of Codetol

Codetol is utilized to provide symptomatic relief across two distinct therapeutic domains, offering support when acute symptoms interfere with comfort and function. The use of the compound involves easing symptoms related to pain and supporting cough suppression.

It is relevant in clinical settings that involve acute or unstable symptom patterns, commonly used for managing mild to moderate acute physical pain and for supporting the management of persistent, non-productive coughing. Applied in scenarios where additional management of discomfort is required, the medication helps address symptom clusters that may become intense or disruptive.

Support for Managing Mild to Moderate Acute Physical Pain

This domain covers the medication's use in providing analgesic relief for symptoms related to physical discomfort that are generally classified as mild to moderate in intensity. Codetol is commonly used when short-term symptomatic assistance is needed for conditions associated with acute or disruptive episodes, such as managing pain following dental procedures, minor surgeries, or specific musculoskeletal injuries. This use may contribute to supporting comfort during periods of heightened symptoms, assisting patients in coping more steadily with difficult episodes of acute physical suffering.


Support for Managing Persistent, Non-Productive Coughing

Codetol is relevant across therapeutic areas where short-term symptomatic assistance is appropriate for managing a disruptive cough. It helps address groups of symptoms that cluster into patterns of persistent, dry (non-productive) coughing. Applied in cases where these symptoms create noticeable interference with daily stability, the medication provides support that helps ease the overall symptom burden and may assist with symptoms that interfere with rest during symptomatic episodes.

Quick Fact: Relevant for Acute Discomfort and Irritating Cough.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility for Codetol is strictly governed by official regulatory criteria, focusing on age, genetic risk, and pre-existing severe health conditions. The medicine is generally permitted for use in adults 18 years and older. Use in adolescents aged 12 to 18 is restricted, typically only for acute moderate pain that cannot be managed with non-opioid pain relievers.

Populations for Whom Use is Contraindicated

Group Prohibition Status (Official Labeling)
Pediatric Patients Contraindicated for all children younger than 12 years of age.
Postoperative Adolescents Contraindicated for pain management following tonsillectomy or adenoidectomy in those under 18 years.
Metabolic Status Contraindicated for individuals known to be CYP2D6 ultra-rapid metabolizers.
Physiological Status Contraindicated for patients with acute/severe bronchial asthma, significant respiratory depression, or paralytic ileus/GI obstruction.

Special Populations and Conditional Use

Regulatory bodies classify Codetol as Not Recommended for breastfeeding mothers due to the potential risk of serious adverse reactions, including infant death, particularly if the mother is an ultra-rapid metabolizer. Use requires caution and monitoring in elderly, frail, or debilitated patients due to increased risk of breathing difficulties. Restrictions also apply to patients with severe renal or hepatic impairment, and use is limited for adolescents with risk factors like obstructive sleep apnea.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Codetol (Codeine-containing products) interactions are primarily based on its effects on the central nervous system (CNS) and its metabolism by liver enzymes.

Interaction Category Risk Classification Mechanism and Constraint
CNS Depressants (e.g., alcohol, benzodiazepines, other opioids, non-benzodiazepine hypnotics) Serious/Life-Threatening Additive CNS depression leading to profound sedation, respiratory depression, coma, and death. Concomitant use should be limited to the minimum dosage and duration required.
Monoamine Oxidase Inhibitors (MAOIs) Contraindicated MAOIs, and use within 14 days of stopping MAOIs, is contraindicated due to the potential for serious adverse reactions.
Serotonergic Drugs (e.g., SSRIs, SNRIs) Serious Risk Increased risk of Serotonin Syndrome, a potentially life-threatening condition involving changes in mental status and neuromuscular activity.
CYP450 Enzyme Inhibitors/Inducers Altered Response Codeine is metabolized by CYP2D6 to its active metabolite, morphine. Co-administration of CYP2D6 inhibitors may reduce analgesic effect, while CYP3A4 inhibitors may increase codeine levels. Adjustments and close monitoring for signs of toxicity or lack of effect are necessary.
Mixed Agonist/Antagonist Opioids Avoid Use Products like nalbuphine or pentazocine may reduce the analgesic effect of Codetol or precipitate withdrawal symptoms.

Mechanism of Action

Pro-Drug Activation and Central Nociceptive Modulation

The primary mechanism for Codeine's action is its conversion into the active metabolite, Morphine, a process catalyzed by the liver enzyme Cytochrome P450 2D6 (CYP2D6). Morphine then acts as a full agonist at central mu-opioid receptors (MOR) in the brain and spinal cord, initiating a cascade of molecular events that hyperpolarize neurons and inhibit the release of excitatory neurotransmitters like Substance P. This engagement of the Descending Pain Modulatory System leads to the physiological consequence of modulation of nociceptive signal transmission.


Distinct Modulation of the Medullary Cough Reflex Center

A second, distinct mechanistic domain involves modulation of the medullary cough center located in the brainstem. Codeine and its metabolites directly influence the opioid receptors in this region, causing an inhibition of the center's neuronal excitability. This action directly elevates the physiological cough threshold via inhibition of neuronal activity within the reflex arc.


Mechanistic Constraints: Enzyme Polymorphism and Tolerance

The efficacy of the drug is biologically constrained by the genetic polymorphism of CYP2D6, meaning individuals who are poor metabolizers fail to produce sufficient active metabolite, constraining the extent of mu-opioid receptor engagement. Furthermore, chronic activation of the MOR system can lead to receptor desensitization and down-regulation, resulting in tolerance and a progressive reduction in the physiological effect.

Dosage and Administration Information

Codetol is administered via the oral route using immediate-release tablets (15 mg, 30 mg, and 60 mg) or oral solution. The standard adult dose for pain management ranges from 15 mg to 60 mg per dose. This is typically taken up to every 4 to 6 hours as needed, not exceeding a maximum of 360 mg in a 24-hour period for opioid-naive patients. Dosing is generally individualized and titrated to the minimum quantity required to achieve the necessary analgesic effect.

The overarching principle for use is to ensure administration at the lowest effective dosage for the shortest duration possible consistent with treatment goals. For patients with known hepatic or renal impairment, a reduced initial dosage and caution during administration are generally indicated. The oral solution must be measured precisely using a calibrated milliliter measuring device to ensure dosage accuracy; household teaspoons should not be used.

Restrictions apply to specific populations. The medicine is contraindicated for use in children younger than 12 years of age. Furthermore, it must not be used in patients younger than 18 years following tonsillectomy or adenoidectomy surgery. Upon discontinuation, the dose should be gradually reduced, or tapered, in physically dependent individuals instead of being abruptly stopped.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Codetol

Evidence for Use in Managing Mild to Moderate Acute Physical Pain

The clinical evaluation of Codetol for pain management has primarily involved short-term, randomized controlled trials (RCTs) and meta-analyses. These studies were designed to compare codeine, often in fixed-dose combinations, against a placebo or comparator drugs. Research focused on outcomes related to physical discomfort, examining patient-reported pain intensity and the need for rescue analgesics. Findings describing patterns observed where codeine-containing combinations were studied against placebo regarding pain measurements in these specific acute settings. Follow-up durations were typically limited to hours or a few days, meaning that long-term outcomes are not fully established. The ability to predict individual responses remains limited, as findings describe group patterns, not personal outcomes.

Evidence for Use in Suppression of Persistent, Non-Productive Coughing

The evidence base for Codetol was studied in research contexts involving persistent, non-productive coughing. This area of research relies on a limited number of randomized controlled trials and systematic reviews that analyzed outcomes related to cough frequency and cough severity. Studies reported how symptoms evolved in the observed populations, but findings were mixed across different analyses. When compared to a placebo in certain trials, research describes patterns related to variable measurements in the context of cough symptom research. The overall certainty regarding the evidence quality in this area remains low, as concluded by reviewers.

What Remains Unclear or Uncertain in the Research

Official regulatory summaries highlight several areas where certainty remains low or where research is ongoing. These research limitation frames include: Sample sizes were modest in many of the key trials, particularly for the cough indication; evidence quality varies across studies, leading to mixed findings; and limited data are still emerging regarding the variability in patient responses. The research provides context only for acute management, but extended periods of use are not addressed by the available data. Furthermore, while use in adolescents (ge 12 years) has been explored, data for certain groups remain insufficient to draw wide conclusions.

Key Studies & References

  1. Codeine - MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Codetol (FAQ)

Q: Is Codetol considered a strong pain reliever, or is it for mild pain?

Codetol, which contains the active ingredient codeine, is officially approved for the management of mild to moderate pain. Its classification as an opioid analgesic and antitussive is based on its ability to modulate pain perception in the central nervous system. It is not typically classified or used for the treatment of severe pain.


Q: How quickly can a person expect to feel the effects after taking Codetol?

According to official product information, the pain-relieving effects of immediate-release Codetol typically begin to be felt within a reasonable time after taking a dose. The maximum analgesic effect is generally reached about two hours after administration. Individual responses can vary.


Q: What is the usual duration of effect for a single dose of Codetol?

The pain-relieving effect from a single dose of immediate-release Codetol is generally expected to last for approximately four to six hours. This duration helps inform the typical spacing between doses. If the relief seems to wear off sooner, this should be discussed with a healthcare provider.


Q: Does taking Codetol with food change how quickly it starts working?

Official pharmacological studies indicate that taking codeine with a high-fat, high-calorie meal does not significantly change the rate or extent to which the medicine is absorbed by the body. Therefore, the effect of food on the time it takes for Codetol to start working is typically not considered a major factor.


Q: What are the signs of a non-severe allergic reaction to Codetol?

While severe allergic reactions like anaphylaxis are possible, documented adverse reactions often involve the skin. The safety profile notes that reactions such as itching (pruritus) and a rash may occur. The development of any signs suggestive of an allergic reaction is a matter that should be discussed with a healthcare provider.


Q: What should be done about the common side effects of Codetol, like constipation or nausea?

Common side effects like constipation and nausea are documented in the official safety information. Any occurrence of these effects should be discussed with a healthcare provider for appropriate assessment and to explore general management strategies. Official guidelines emphasize using the lowest effective dosage for the shortest duration possible.


Q: Are there any warnings about Codetol use during pregnancy or while breastfeeding?

Yes, official warnings exist for both situations. Use during pregnancy may potentially harm the fetus, and prolonged use can lead to Neonatal Opioid Withdrawal Syndrome in the infant. Use in breastfeeding mothers is generally not recommended due to the risk of serious side effects in the infant.


Q: Can Codetol affect hormone levels or fertility with long-term use?

Studies and official information indicate that long-term opioid use may be associated with decreased hormone levels, such as secondary adrenal insufficiency. The official data from nonclinical studies did not evaluate effects on fertility.


Q: What are the possible long-term side effects of Codetol use?

The duration-related safety profile officially documents that prolonged or chronic use is associated with the development of physical dependence and tolerance. Tolerance is when the body requires a higher dose to achieve the same effect. The risk of Adrenal Insufficiency is also noted with long-term use.


Q: Can Codetol affect a person's ability to drive or operate machinery?

Yes, regulatory documents clearly state that Codetol can cause side effects like sedation, dizziness, and impaired mental and physical abilities. For this reason, official warnings advise caution against performing hazardous tasks, such as driving or operating heavy machinery, while taking this medicine.


Q: Are there any specific foods or drinks, besides alcohol, that should be avoided with Codetol?

While interactions with many specific foods are not usually highlighted, some official sources advise caution regarding grapefruit and grapefruit juice. Consuming these products may potentially increase the blood levels of codeine, which could alter its effects.


Q: Can Codetol increase the risk of breathing problems, and for whom is this a bigger concern?

Yes, it carries a warning about the risk of life-threatening respiratory depression, meaning dangerously slow or shallow breathing. This risk is greater for specific populations, including the elderly, debilitated patients, and those with certain chronic pulmonary diseases.


Q: Is it true that Codetol's effectiveness can be different for different people due to genetics?

Yes, official warnings address this. The effectiveness is dependent on how the body converts codeine into its active form using a liver enzyme (CYP2D6). Genetic differences in this enzyme mean some people convert the drug faster or slower than others, resulting in differing levels of pain relief or side effects.


Q: What does it mean if Codetol seems to stop working for pain relief over time?

If the medicine seems to lose its effectiveness over time, this can be a sign of tolerance. Tolerance is a documented condition associated with prolonged use where the body adapts, requiring a larger dose to achieve the same pain-relieving effect. This change in effect is a matter that should be discussed with a healthcare provider.


Q: Can Codetol cause a feeling of being unusually tired or 'washed out' afterward?

Yes, the official safety profile documents common side effects that relate to this feeling. These include drowsiness, sedation, lethargy, and lightheadedness. These central nervous system effects are normal documented possibilities when taking this medication.


Q: Is it normal to have increased sweating or itching while taking Codetol?

Official safety data lists both sweating (diaphoresis) and itching (pruritus) as documented adverse reactions. While they are not classified as the most common effects, they are known possibilities when using codeine-containing products.


Q: Why is Codetol sometimes combined with other ingredients like acetaminophen?

Codetol is frequently manufactured as a fixed-dose combination product with non-opioid active ingredients, such as acetaminophen. This combination is typically used to enhance the overall pain-relieving effect by targeting pain through different mechanisms simultaneously.


Q: Are there different forms of Codetol, such as immediate-release versus extended-release?

Yes, official dosage and strength information shows that codeine is available in different formulations. These include both an immediate-release tablet or solution, which works quickly, and sometimes an extended-release form, which is designed to release the medicine slowly over a longer period.


Q: Is Codetol generally safe for older adults or the elderly population?

Official warnings state that use in elderly patients requires caution and close monitoring. This is because older adults face a higher risk of adverse effects, including serious complications like respiratory depression and confusion. Treatment typically begins at a reduced initial dosage.


Q: How does Codetol affect the central nervous system?

Codetol is classified as a central nervous system (CNS) depressant. Its effects include reducing pain perception, but it can also cause sedation, dizziness, and the potential for profound sedation. This is the basis for warnings about combining it with other CNS depressant drugs.


Q: Is there a maximum time length that Codetol should be used for, even if prescribed?

The official principle for use is to administer the lowest effective dosage for the shortest duration possible, consistent with treatment goals. While no specific universal maximum number of days is defined on the label, the emphasis is placed on minimizing the duration of use.


Q: Is it normal to feel a bit restless or anxious if a dose of Codetol is missed?

If the medicine is stopped abruptly after chronic use, regulatory documents warn that a withdrawal syndrome can occur. Symptoms of this withdrawal may include feelings of restlessness and anxiety. Any such changes are a matter that should be discussed with a healthcare provider.


Q: Can Codetol cause issues with sleep, such as insomnia?

While the medicine commonly causes drowsiness and sedation, the official list of adverse reactions also documents the possibility of trouble with sleeping (insomnia). This indicates that the drug's effect on sleep patterns can be variable.


Q: Is it possible for Codetol to affect blood pressure?

Yes, official warnings indicate that Codetol can cause severe hypotension (low blood pressure). Due to this potential effect, monitoring is necessary, particularly when a patient starts taking the medication or when the dosage is adjusted.


Q: Does Codetol have any reported impact on mental health or mood?

Official documents report that adverse reactions include confusion. Furthermore, combining it with certain other drugs can lead to the potentially serious Serotonin Syndrome, and long-term use has been associated with depressive symptoms.


Q: Is it possible to develop a tolerance to the effects of Codetol?

Yes, tolerance is a condition officially associated with the prolonged or chronic use of codeine-containing products. This means the body may need a larger amount of the medicine to achieve the same effect over time.


Q: What common household medicines or herbal products should be checked for interactions with Codetol?

Official information advises caution with any substance that is a CNS depressant, which includes many antihistamines or certain cold and allergy medicines. Additionally, products that affect the CYP2D6 or CYP3A4 liver enzymes may also require checking for potential interactions.


Q: Is Codetol ever used in palliative care settings?

Official sources recognize codeine's role in pain treatment, and some documentation references its use in the management of pain, including for ongoing cancer pain or in palliative care settings. Its use is focused on achieving therapeutic comfort.


Q: Can Codetol cause a change in pupil size?

Yes, as an opioid, one of the signs of its toxicity or overdose documented in official information is miosis, or the constriction and shrinking of the pupils to a pinpoint size.


Q: Is it important to monitor for signs of confusion or changes in awareness while taking Codetol?

Yes, official warnings advise monitoring for signs of sedation and impaired consciousness. This is particularly important for patients who have head injuries or already have impaired consciousness, as Codetol can worsen these symptoms.


Q: Can the effectiveness of Codetol be reduced by taking other medications?

Yes, regulatory documents indicate this is possible. If Codetol is taken alongside medications that are CYP2D6 inhibitors (which block the necessary enzyme), it can prevent the body from converting enough of the medicine into its active form. This may result in a reduced analgesic effect.


Q: Can taking Codetol lead to dry mouth?

Yes, dry mouth (xerostomia) is listed in the official adverse reactions section as a documented potential side effect of codeine-containing products.


Q: What should I know about combining Codetol with other medications that cause drowsiness?

The most serious warnings apply to combining Codetol with other CNS depressants (medications that cause drowsiness or slow down the central nervous system). This combination carries a documented risk of profound sedation, respiratory depression, coma, and even death.

How should Codetol be stored and disposed of?

How to Store and Dispose of Codetol?

As a controlled substance, Codetol requires specific handling defined by regulatory authorities.

Official Storage Requirements

Codetol must be stored securely at room temperature (typically 20 C to 25 C), away from excess heat, moisture, and light. It is mandatory to keep the medication in its original container and ensure the lid is tightly closed. Storage locations such as bathrooms and freezers are prohibited, and the product must be kept out of the sight and reach of children due to the high risk of fatal accidental ingestion.

Official Disposal Rules

For disposal of unused or expired Codetol, the most secure method is a drug take-back program. If a program is not immediately available, the FDA permits flushing down the toilet as an alternative to prevent misuse and accidental exposure, given the medication's potential for harm.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Codetol found in:

A-Z Index: